While phase I/II clinical trials with olaparib have reported impressive objective response rates in patients with advanced BRCA1/2 mutation ovarian cancer, not all patients achieve the same level of benefit to olaparib. This evidence concerns the gene BRCA1 and ovarian carcinoma.